Andre Hoffmann Net Worth: Estimate, Evidence, and Updates

André Hoffmann's net worth is estimated at approximately $9.38 billion as of December 2025, according to figures aligned with Bloomberg's Billionaires Index and referenced by Wikipedia's entry on him. That number is driven almost entirely by his stake in Roche Holding Ltd, one of the world's largest pharmaceutical and diagnostics companies, where he sits on the Board of Directors as Vice-Chairman and represents a family shareholder group that collectively controls nearly 65% of issued Roche shares.

Which André Hoffmann are we talking about?

The name André Hoffmann is not unique, so it is worth being clear upfront. The subject most search results converge on is the Swiss billionaire André Hoffmann (born 1958), a grandson of Roche founder Fritz Hoffmann-La Roche and a prominent environmental philanthropist. He is not to be confused with other individuals sharing a similar name. If you arrived here researching a different André Hoffmann, this profile specifically covers the Swiss Roche heir.

Beyond Roche, this André Hoffmann is widely known for his conservation work. He serves as President of Fondation Tour du Valat, a wetlands research foundation in the Camargue region of France. He has also led the MAVA Foundation (a Swiss biodiversity philanthropy), and holds board positions with organizations including the Capitals Coalition, the B-Team, Peace Parcs, and the Givaudan Foundation. The World Economic Forum profiles him in this capacity as well. These roles are relevant to his public identity but have limited direct impact on his personal net worth compared to the Roche stake.

What net worth actually means, and how estimates are built

Net worth is total assets minus total liabilities. For someone like André Hoffmann, whose wealth is largely concentrated in publicly traded shares of a single company, the calculation sounds simple: multiply shares held by share price, subtract any known debts. In practice, estimating his individual slice of the Roche family pool is more complex than that.

Roche publicly discloses that a shareholder group with pooled voting rights held 69,318,000 Roche Holding shares as of December 31, 2025, representing 64.97% of issued shares. That group consists of multiple named family members, including André Hoffmann, as well as a charitable entity (Wolf Foundation) and Artuma Holding LLC. What Roche does not disclose is each individual's exact slice of that pool. This means any individual net-worth figure for André Hoffmann requires an assumption about what proportion of the pool he personally controls. Bloomberg's Billionaires Index uses proprietary modeling for this, and Bloomberg has noted that Hoffmann himself declined to comment on his net worth, confirming that the figure is an estimate rather than a self-reported disclosure.

Bloomberg updates its Billionaires Index every business day, so the figure shifts continuously with Roche's share price. The $9.38 billion figure anchored to December 2025 is a point-in-time snapshot, not a fixed number.

The current net worth estimate and what drives it

The most credible current range for André Hoffmann's net worth sits in the $8 billion to $10 billion band, with Bloomberg's December 2025 estimate of $9. Ray Halbritter net worth estimates are often discussed in the context of his work and business interests, though figures can vary by source. 38 billion as the most cited specific figure. Here is what drives that number:

• Roche shareholding: The dominant asset. The pooled-voting family group owns roughly 69.3 million Roche Holding shares. Even a modest individual allocation within that group translates to billions given Roche's market capitalization, which regularly places it among Europe's largest companies by value.
• Roche dividends: Roche has a long track record of paying substantial dividends. Its Half-Year and Annual Reports disclose per-share dividend figures approved at shareholder meetings. A large block of shares generates very significant annual cash income, which compounds wealth over time.
• Leadership role: André Hoffmann serves as Vice-Chairman of Roche's Board of Directors. Board compensation at this level adds income, though it is marginal relative to the equity stake.
• Foundation and philanthropy: His roles at Tour du Valat, MAVA Foundation, and others are mission-driven and not personal wealth generators. However, they reflect stewardship of family capital deployed philanthropically, which some net-worth models may handle differently (excluding foundation-held assets from personal net worth).
• Private assets: Real estate, private investments, and liquid holdings outside Roche are not publicly disclosed. These likely add to the total but are excluded from most published estimates due to lack of data.

Where to verify the numbers yourself

If you want to check or update this estimate, these are the most reliable sources to work from:

1. Roche's Share and Bond Information page: This is the primary source for the pooled-voting group's aggregate share count, the names of members including André Hoffmann, and ownership percentages as of the most recent year-end disclosure.
2. Roche's Annual Report: Published each year, this contains corporate governance sections, shareholding tables, and dividend-per-share data. The 2025 Annual Report is available via Roche's Corporate Publications hub.
3. Bloomberg Billionaires Index: Bloomberg's profile for André S. Hoffmann is updated daily on business days and reflects current Roche share prices. It is the most actively maintained public estimate of his individual wealth.
4. GuruFocus (Andre S. Hoffmann page): GuruFocus tracks insider holdings and trading behavior for public company directors. Its methodology differs from Bloomberg's and is useful for cross-referencing but applies different assumptions about private wealth.
5. Changes in Roche Shareholder Pool documents: Roche and affiliated press mailings have published notices about structural changes to the family pool. These are worth reviewing if you want to understand whether Hoffmann's individual allocation within the group has shifted.
6. SRF (Swiss public broadcaster) and Swiss financial press: SRF has covered André Hoffmann in the context of his Roche heritage and conservation work. Swiss business media provide country-specific context that international outlets sometimes miss.
7. Wikipedia's André Hoffmann (businessman) entry: Not a primary source, but it aggregates Bloomberg citations and is a reasonable starting point for recent figures and biographical verification.

How his wealth could change from here

Because André Hoffmann's net worth is so heavily tied to a single equity stake, the biggest variable is Roche's share price. Roche operates in global pharmaceutical and diagnostics markets where regulatory decisions, drug approvals or failures, and competitive pressures can move the stock significantly. A 10% move in Roche shares could shift the estimated net worth by hundreds of millions of dollars.

Beyond market movements, several structural factors could change the picture over time:

• Dividend income: Roche's consistent dividend policy means that each year the family pool receives large cash distributions. These accumulate and can be redeployed into other assets, gradually diversifying the wealth base.
• Shareholder pool restructuring: Roche has published documentation about changes in the family's pooled-voting shareholder structure. If family members transfer or sell shares, if the pool adds or loses members, or if charitable foundations within the pool change their allocations, individual estimated stakes will shift.
• Roche corporate events: Mergers, acquisitions, divestitures, or major restructurings at Roche would affect the stock's valuation and therefore Hoffmann's estimated net worth directly.
• Philanthropic transfers: Large transfers of personal assets to foundations reduce personal net worth even if they increase the total resources deployed under the family's umbrella. Different estimation sites handle this inconsistently.
• Estate and succession planning: As a generational wealth holder, transfers between family members or trusts could reallocate who holds what fraction of the pool, affecting individual estimates.

Why different sites give very different numbers

This is probably the most practically useful thing to understand if you are doing any kind of research. Net-worth figures for André Hoffmann vary across sites for several distinct reasons, and not all of them reflect bad data. Because it is tied largely to Roche’s pooled holdings, the André Hoffmann net worth estimate can differ meaningfully depending on assumptions used by each site Andre Hoffmann net worth. Here is the breakdown:

The bottom line: the $9. For those specifically asking about Roy Halston Frowick’s net worth, it is important to rely on credible, source-backed figures rather than guesswork roy halston frowick net worth. 38 billion figure from Bloomberg's December 2025 estimate is the most methodologically grounded publicly available number, but it carries real uncertainty because the individual allocation within the family pool is not disclosed. Treat any figure in the $8 billion to $10 billion range as reasonable for late 2025, and expect it to drift with Roche's share performance.

Next steps to research and validate the latest estimate

If you need the most current and defensible number, here is a practical workflow you can run today:

1. Pull today's Roche Holding share price from any major financial data provider (Bloomberg, Reuters, SIX Swiss Exchange).
2. Find the most recent year-end disclosure of the pooled-voting group's aggregate share count from Roche's Share and Bond Information page. The 2025 figure is 69,318,000 shares.
3. Calculate the pool's total market value: share price multiplied by 69,318,000.
4. Check Bloomberg's Billionaires Index profile for André S. Hoffmann to see the most current individual estimate and compare it to your pool-total calculation. The gap between pool total and individual estimate tells you what fraction Bloomberg is attributing to him.
5. Cross-reference Roche's most recent Annual Report for dividend-per-share data to understand annual cash income from the stake.
6. Note the date of any figure you use and flag it as a point-in-time estimate, not a static fact.
7. For biographical verification and role confirmation, check Roche's Board of Directors page, the World Economic Forum's profile, and Tour du Valat's governance page.

Researching the wealth of other business figures adjacent to this space, including executives and heirs tied to large family-controlled companies, often involves similar challenges around pooled ownership structures and philanthropy-adjusted estimates. If you are comparing this approach to another person in similar financial spotlight, you may also want to review rob havenstein net worth. Net worth figures for Roy Halston are also typically modeled from public data and private ownership assumptions, so the exact number can vary by source Roy Halston net worth. If you want more context on how estimates like this are framed, see the ray huber net worth discussion for comparison. The same methodological principles apply: anchor on public equity disclosures, understand the pool structure, and treat any individual slice as an estimate rather than a confirmed figure. These principles can also help when you’re looking into Ron Huberman’s net worth and how estimates are derived net worth estimates.